<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314403</url>
  </required_header>
  <id_info>
    <org_study_id>MGH Tolerance Trial</org_study_id>
    <nct_id>NCT02314403</nct_id>
  </id_info>
  <brief_title>Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of a combination kidney and bone marrow
      transplant from a haplo-identical related donor. An investigational medication and other
      treatments will be given prior to and after the transplant to help protect the transplanted
      kidney from being attacked by the body's immune system
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful withdrawal of immunosuppression</measure>
    <time_frame>5 Years</time_frame>
    <description>The Primary Outcome is: The induction of transient mixed chimerism and renal allograft tolerance (24 consecutive months off of immunosuppression)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>A selective T-cell (lymphocyte) costimulation blocker</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>A T-Cell Depleting Agent</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>B-Cell Depleting Agent</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thymic Irradiation</intervention_name>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined Bone Marrow/Kidney Transplantation</intervention_name>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18-60 years of age

          -  Candidate for a living-donor renal allograft from an HLA mismatched donor

          -  First or second transplant with either a living donor or cadaveric transplant as the
             first transplant.

          -  Use of FDA-approved methods of contraception by all recipients from the time that
             study treatment begins until 104 weeks (24 months) after renal transplantation.

          -  Ability to understand and provide informed consent.

          -  Serologic evidence of prior exposure to EBV.

        Exclusion Criteria:

          -  ABO blood group-incompatible renal allograft.

          -  Evidence of anti-HLA antibody within 60 days prior to transplant as assessed by
             routine methodology (AHG and/or ELISA)

          -  Leukopenia or thrombocytopenia.

          -  Positive for HIV-1, hepatitis B core antigen, or hepatitis C virus; or positivity for
             hepatitis B surface antigen.

          -  Cardiac ejection fraction &lt; 40% or clinical evidence of insufficiency.

          -  Forced expiratory volume FEV1 &lt; 50% of predicted.

          -  Lactation or pregnancy.

          -  History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of
             the cervix.

          -  Underlying renal disease etiology with a high risk of disease recurrence in the
             transplanted kidney (such as focal segmental glomerulosclerosis, type I or II
             membranoprolifertive glomerulonephritis).

          -  Prior dose-limiting radiation therapy.

          -  Known genetic disease or family history that may result in greater sensitivity to the
             effects of irradiation, or a physical deformity that would preclude adequate shielding
             or appropriate dosing during the irradiation component of the conditioning regimen.

          -  Enrollment in other investigational drug studies within 30 days prior to enrollment.

          -  Abnormal (&gt;2 times lab normal) values for (a) liver function chemistries (ALT, AST,
             AP), (b) bilirubin, (c) coagulation studies (PT, PTT).

          -  Allergy or sensitivity to any component of belatacept, ATG, tacrolimus, or rituximab.

          -  Maintenance immunosuppression within 3 months prior to conditioning other than
             physiological doses of steroids, defined as â‰¤ 50 mg of hydrocortisone or dose
             equivalent.

          -  The presence of any medical condition that the investigator deems incompatible with
             participation in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuo Kawai, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerry Crisalli, RN BSN CCRC</last_name>
    <phone>617-643-4087</phone>
    <email>kcrisalli@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Crisalli</last_name>
      <phone>617-643-4087</phone>
      <email>kcrisalli@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21666482?dopt=Abstract</url>
    <description>Kawai T, Cosimi AB, Sachs DH. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant. 2011 Aug;16(4):366-71.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21839648?dopt=Abstract</url>
    <description>Sachs DH, Sykes M, Kawai T, Cosimi AB. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol. 2011 Jun;23(3):165-73.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/18216355?dopt=Abstract</url>
    <description>Kawai T, (et.al.) HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008 Jan 24;358(4):353-61.</description>
  </link>
  <link>
    <url>https://www.immunetolerance.org/sites/files/Kawai_AJT_2014.pdf</url>
    <description>Kawai T, (et. al.) Long-Term Results in Recipients of Combined HLA-Mismatched Kidney and Bone Marrow Transplantation Without Maintenance Immunosuppression</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Tatsuo Kawai, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Surgery, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

